Neither losartan nor mirabegron reduced the LV expression of Col1a1 significantly as compared to the CKD or sham-operated groups; however, it showed a tendency of decrease in the mirabegron-treated CKD group as compared to the CKD group. This evidence concerns the gene COL1A1 and chronic kidney disease.